Mobiflexi ingredients: seven compounds, seven trial doses

Why branded raw materials and not commodity extracts

AprèsFlex, Meriva and UC-II are proprietary ingredients with their own human trials, their own manufacturing specification and a certificate per batch. A generic curcumin costs the formulator a fraction of Meriva and delivers perhaps a tenth of it into the bloodstream. On a label, both read as curcumin.

That single fact explains almost the whole price gap between a £7 bottle off a Holland & Barrett shelf and this one. If you have a competitor's label to hand, compare milligrams per full daily dose — not the number of ingredients listed, and not the word 'complex' doing a lot of quiet work in a proprietary blend.

What is not in it

Manufacture and testing

Made in the EU in GMP-certified facilities, with each batch sent to an independent laboratory for heavy metals and microbiology. That matters more for glucosamine than for most ingredients: shellfish-derived raw material is the classic route for cadmium and lead into a joint supplement, and it is the first thing a proper COA reports.

The certificate of analysis for your batch is available on request — email customer service with the batch number stamped on the base of the bottle, and it should reach you in a few working days. A supplier that hesitates over that is telling you something.

Ingredients and doses

• AprèsFlex® Boswellia serrata — 400 mg. Standardised to 65% boswellic acids. In the randomised data the relief signal showed up on day seven, which makes it the fastest-acting thing here and the reason anyone notices anything before week four. A branded extract with batch documentation, not bark powder of unknown acid content.
• Meriva® Curcumin (phytosome) — 250 mg. Curcumin bound to phospholipids, giving roughly 29 times the plasma availability of ordinary extract. Plain curcumin is largely an expensive colouring; the phytosome does the job piperine is usually recruited for, more gently on the stomach.
• Glucosamine sulphate — 1500 mg. The full daily dose from the clinical literature, in the sulphate form used in the European trials rather than the hydrochloride of some American ones — a distinction that matters, since most negative findings, including the NIH-funded GAIT trial, involved formulations that are not directly comparable. Sulphate salts also carry the sulphur the cartilage matrix needs.
• Chondroitin sulphate — 1200 mg. Pairs with glucosamine rather than repeating it: glucosamine supplies the material, chondroitin holds the water that keeps the tissue compressible. The combination is better supported in the literature than either compound alone — which is also where the GAIT subgroup analysis pointed.
• Hyaluronic acid — 80 mg. The viscous component of synovial fluid. Taken by mouth it works far more slowly than a clinic injection — and without the eighteen-week waiting list that now precedes most of those. Reports of movement feeling smooth instead of grinding come from this line.
• UC-II® undenatured type-II collagen — 40 mg. A different mechanism entirely: oral tolerance. Intact type-II collagen trains the immune system to stop attacking cartilage in gut-associated lymphoid tissue, so the dose is deliberately tiny. 40 mg is the studied figure; more adds nothing, because this is not about supplying building blocks.
• BioPerine® (piperine) — 5 mg. Raises the absorption rate of several of the other compounds. A very small quantity with an outsize effect on bioavailability, and the sensible companion to a formula built around a phytosome.